TABLE 2.

Therapies targeted MYH9.

Therapies	Tumors	Mechanism	References
Cinobufotalin	Lung adenocarcinoma	Upregulate the expression of ENKUR through the inhibition of PI3K/AKT/c-Jun-mediated transcriptional repression	Liu et al. (2022)
	Nasopharyngeal carcinoma		Hou et al. (2022b)
	Gastric cancer		Liu et al. (2020a)
DT-13	Gastric cancer	Combine with topotican promoted the degradation of epidermal growth factor receptor	Yu et al. (2019)
	Lung cancer	Inhibit human lung cancer metastasis under hypoxic condition	Wei et al. (2016)
	Breast cancer	Inhibit migration by regulating stromal cells in the TME	Gao et al. (2020b)
Immunotherapy	Lung adenocarcinoma	YY1-FGL1-MYH9 axis	Tang et al. (2022)
	Colorectal cancer	MAP7D2 interacting with MYH9, MAP7D2 knockdown increased the infiltration of CD8 CTLs, thereby inhibiting tumor progression	Wu et al. (2023)
Amidated fullerenes		Resulting in altered MYH9 localization, and also inhibiting metastasis-associated EMT	Huo et al. (2022), Li et al. (2023a), Zhou et al. (2020b)
J13		Weakening MYH9-actin interactions and deactivating the molecular motors to promotes the mitochondrial division process, leading to an imbalance in its dynamics and significantly inhibiting cancer cell survival, proliferation and migration	Qian et al. (2021)
ITE	Glioma	Agonizing endogenous aromatic hydrocarbon receptors and blocks multiple modes of cell migration	Zhao et al. (2020)
Astrocystin	Gastric cancer	Targeting cytosolic MYH9-induced CTNNB1 transcription to promote anti-apoptosis as well as metastasis	Ye et al. (2020)
Apatinib	Glioma	Target platelet-responsive protein 1 (THBS1), thereby inhibit glioma cell malignancy through its interaction with MYH9	Yao et al. (2021)